close

Enter

Log in using OpenID

Nanobodies Market

embed
Nanobodies are considered to be one of the best technology in the fields of research, diagnostics and therapy especially in cancer research.
Nanobodies Market Growth By Global Players Novo
Nordisk A/S, Merck & Co., Inc., Merck KGaA
Nanobodies are considered to be one of the best technology in the fields of research,
diagnostics and therapy especially in cancer research. These technology was developed from
antigen binding fragments, originating from Camelid heavy-chain antibodies. These molecules do
not have light chains, which is an essential part of antibodNanobodies Market Growth By
Global Players Novo Nordisk A/S, Merck & Co., Inc., Merck KGaAy found in humans. Based on
the above finding, nanobodies molecule containing single-domain only were developed, and
these molecules contain functional and structural properties similar to heavy chain antibodies.
These molecules have several advantages as compared to the conventional antibodies such as
small-size, nano to picomolar affinities, and multiple route of administration. Ablynx, which is
acquired by Sanofi S.A., is one of the leading company in this market.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1680
Nanobodies Market Drivers
Currently, no products are available in the market, but there are multiple products in the
pipeline including few in very late stage of clinical trials. For instance, marketing authorization
application for Caplacizumab for the treatment of acquired thrombotic thrombocytopenic
purpura (aTTP) has been submitted to European Medicine Agency (EMA) in February 2017. The
product, Caplacizumab, is expected to be launched in Europe in 2018. Moreover, the company,
Ablynx, is expected to file for biologic license agreement to the U.S. Food and Drug
Administration (FDA) in 2018, and is expected to launch this product in U.S. in 2019. Both,
Europe and U.S. are the key markets for any biologics including monoclonal antibodies and are
expected to be the high revenue generating market for nanobodies. Hence, approval by
regulatory bodies in Europe and U.S. to Caplacizumab in very near future (i.e. 2018, 2019) is
expected to drive the growth of global nanobodies market. As per the company, Ablynx,
estimates the product has potential to generate more than US$ 1 Bn. Furthermore, there are
multiple products in early stage of clinical development i.e. preclinical, phase 0, and phase 1.
Ablynx alone had 8 products in clinical development phase (i.e. phase 0 to phase 3) and overall
45 products in pipeline as of March 2017.
Lucrative potential in the market has motivated leading biotechnology companies such as C.H.
Boehringer Sohn AG & Ko. KG, MERCK KGaA, Merck & Co., Inc., AbbVie, Inc., Novo Nordisk
A/S and Sanofi S.A. to collaborate or enter into a partnership agreement with the nanobodies
manufacturer, Ablynx. In July 2017, Ablynx entered into a research collaboration and licensing
agreement with Sanofi S.A. for the treatment of various immune-mediated inflammatory
diseases. As per the agreement, Sanofi S.A. will get access to Ablynx’s scientists and technology
platforms, and also, to certain drugs in pipeline. Furthermore, in 2015, Ablynx and Merck &
Co., Inc. expanded their collaboration agreement focused on immuno-oncology. In January
2018, Sanofi S.A. made an offer to acquire Ablynx, and the offer was unanimously
recommended by Ablynx board.
Report includes chapters which deeply display the following deliverable about industry :
• Nanobodies Market Research Objective and Assumption
• Nanobodies Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Nanobodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Nanobodies Market, By Regions
• Nanobodies Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Nanobodies Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Nanobodies Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Nanobodies Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Nanobodies Market Regional Analysis
Europe is expected to hold dominant position in global nanobodies market, owing to the first
mover advantage. Marketing authorization application (MMA) to EMA for Caplacizumab was
filed by Ablynx in February 2017, and the company expects to get approval in 2018. If
approved, Europe will be the only market to have nanobodies commercially available. However,
North America is expected to show rapid growth in this market, as the company is planning to
file for biologic license agreement for the same product to U.S. FDA in 2018, and expects to
get approval from FDA by 2019. Once approved in U.S., the company may plan to reap the
maximum benefit out of it. Furthermore, the drug, Caplacizumab, is expected to have better
efficiency compared to both the available treatment (i.e. plasma exchange therapy and
immunosuppressant) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
In Asia Pacific, Japan may take the lead as multiple products such as Caplacizumab,
Vobarilizumab, and ALX- 0171 has successfully gone through initial phase of clinical
development.
Nanobodies Market Restraint
Presently, there are no products in market, and more than two-third products in very early
phase of development, and these products have to go through various phases of clinical
development. Failure in clinical trials for these products or slow approval by the regulatory
bodies in the market may prove to be vital restraint in this market.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/nanobodies-market-1680
Nanobodies Market Key Players
Ablynx (now part of Sanofi S. A.) is the key player in the global nanobodies market. Moreover,
the company is developing various products with leading biology companies such as Novo
Nordisk A/S, Merck & Co., Inc., Merck KGaA, AbbVie, Inc., and C.H. Boehringer Sohn AG &
Ko. KG.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Author
Alex Huge
Alex Huge369   documents Email
Document
Category
Health and Medicine
Views
1
File Size
123 KB
Tags
Nanobodies Market, nanobodies
1/--pages
Report inappropriate content